Nafamostat mesilate attenuates inflammation and apoptosis and promotes locomotor recovery after spinal cord injury.

Hui-Quan DuanQiu-Li WuXue YaoBao-You FanHong-Yu ShiChen-Xi ZhaoYan ZhangBo LiChao SunXiao-Hong KongXin-Fu ZhouShi-Qing Feng

Published in: CNS neuroscience & therapeutics (2018)

Upon NM treatment, the functional and histological outcomes were improved, and microenvironment upon SCI was modulated. As a clinically approved drug, NM holds promise for clinical use after spinal cord injury.

Keyphrases

oxidative stress
spinal cord injury
photodynamic therapy
stem cells
endoplasmic reticulum stress
cell death
cell cycle arrest
metabolic syndrome
big data
light emitting
insulin resistance
drug administration
glycemic control